New medication approved for drug-resistant HIV - Tucson News Now

New medication approved for drug-resistant HIV

  • HealthMore>>

  • The creator of Internet Explorer wants to read your mind with a bracelet

    The creator of Internet Explorer wants to read your mind with a bracelet

    Thursday, June 21 2018 5:15 PM EDT2018-06-21 21:15:03 GMT
    The idea of controlling a computer with your thoughts sounds amazing. A New York startup called CRTL-Labs has created a non-invasive device they claim will make this an everyday reality.
    The idea of controlling a computer with your thoughts sounds amazing. A New York startup called CRTL-Labs has created a non-invasive device they claim will make this an everyday reality.
  • The best wetsuits

    The best wetsuits

    Tuesday, June 19 2018 2:29 PM EDT2018-06-19 18:29:11 GMT
    An investment in a good wetsuit allows you to surf from sunup to sundown, while the right fit keeps you warm and dry all day long. To help you navigate the sea of available options, we've put together a list of the...
    An investment in a good wetsuit allows you to surf from sunup to sundown, while the right fit keeps you warm and dry all day long. To help you navigate the sea of available options, we've put together a list of the best...
  • From J.A.R.V.I.S to John Legend, here are our favorite A.I. assistants

    From J.A.R.V.I.S to John Legend, here are our favorite A.I. assistants

    Thursday, June 21 2018 4:00 PM EDT2018-06-21 20:00:08 GMT
    John Legend will soon be a voice option for Google Assistant, which got us to thinking: What are some of the best voices of technology through the years? From HAL to KITT, our list takes a deep dive into the world...
    John Legend will soon be a voice option for Google Assistant, which got us to thinking: What are some of the best voices of technology through the years? From HAL to KITT, our list takes a deep dive into the world of A.I....

(HealthDay News) -- Trogarzo (ibalizumab-uiyk) has been approved by the U.S. Food and Drug Administration to treat AIDS-causing HIV that has not responded to other antiretroviral medications.

Trogarzo is given intravenously once every 14 days in combination with other antiretroviral drugs, the FDA said Tuesday in a news release.

"While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug resistant HIV, limiting their treatment options," said Dr. Jeff Murray, deputy director of the agency's Division of Antiviral Products.

"Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options," Murray added.

Trogarzo was evaluated in clinical studies involving 40 people who continued to have high blood levels of HIV, despite use of antiretroviral drugs. After 24 weeks of Trogarzo and other drugs, 43 percent of trial participants achieved HIV suppression, the FDA said.

The most common adverse reactions to Trogarzo were diarrhea, dizziness, nausea and rash. More severe side effects included immune system abnormalities.

Trogarzo is produced by TaiMed Biologics, based in Taiwan.

More information

Visit the FDA to learn more about Trogarzo.

Copyright © 2018 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
Powered by Frankly